Emrelis (telisotuzumab vedotin-tllv) / AbbVie - LARVOL DELTA

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. (PubMed, J Clin Oncol) - P1 | "Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC."

Combination therapy • Journal • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). (ASCO 2022) - P1 | "In a phase 1/1b study (NCT02099058) in patients (pts) with c-Met OE NSCLC, Teliso-V alone or in combination with erlotinib demonstrated an acceptable safety profile and antitumor activity. Teliso-V + Osi is well tolerated with an ORR of 58% (67% at 1.9 mg/kg) in pts with c-Met OE NSCLC who progressed on prior Osi."

Clinical • P1 data • Anemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

The impact of immediate prior therapies (Tx) on the safety and efficacy of telisotuzumab vedotin (Teliso-V) in patients (pts) with advanced c-Met protein–overexpressing (OE) non-squamous (NSQ) EGFR wildtype (WT) NSCLC in the phase II LUMINOSITY study (ELCC 2026) - P2 | "Clinical trial identification NCT03539536.Editorial acknowledgement Medical writing support was provided by Joanne Franklin, PhD, CMPP, from Aptitude Health, The Hague, the Netherlands, and funded by AbbVie.Legal entity responsible for the study AbbVie Inc.Funding AbbVie Inc. Table: 34P c-Met OE total Pt (n=22) ICI (n=20) Pt+ICI (n=67) MT–I (n=10) c-Met–I (n=4) ALL (n=127)a ORR, n (%)[95% CI] 9 (40.9)[20.7, 63.6] 11 (55.0)[31.5, 76.9] 13 (19.4)[10.8, 30.9] 4 (40.0)[12.2, 73.8] 2 (50.0)[6.8, 93.2] 39 (30.7)[22.8, 39.5] mPFS, months[95% CI] 5.3[3.0, 8.3] 8.0[3.0, 14.5] 6.7[4.1, 9.6] 11.3[2.7, -] 4.8[3.7, -] 5.9[5.2, 8.3] mOS, months[95% CI] 12.7[3.8, 21.9] 22.9[5.2, 30.3] 14.6[9.0, 17.1] 29.0[7.0, -] 14.7[3.7, -] 14.7[9.9, 17.1] aIncludes 4 pts who received other targeted Tx (different targets [n=3] and pemetrexed [n=1]). -, non-estimable."

Clinical • Metastases • P2 data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • EGFR • MET

Incidence and Severity of Interstitial Lung Disease Associated With Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis (IASLC-WCLC 2025) - "In NSCLC, the highest pooled incidence of any-grade ILD was seen with patritumab deruxtecan (23%) and trastuzumab deruxtecan (22%), followed by datopotamab deruxtecan (9%), telisotuzumab vedotin (7%), and sacituzumab govitecan (1%)...Treatment discontinuation due to ILD in NSCLC was highest with telisotuzumab vedotin combined with erlotinib (36%), followed by trastuzumab deruxtecan (9%) and patritumab deruxtecan (7%)...In SCLC, any-grade ILD incidence was 8% with rovalpituzumab tesirine, with no reported grade ≥3 ILD events...HER2/HER3-targeted, deruxtecan-containing ADCs demonstrated the highest ILD rates, while other ADCs such as sacituzumab govitecan had minimal reported toxicity. These findings highlight the need for agent-specific ILD monitoring and support the consideration of ADC design, including target and payload, when evaluating pulmonary safety and guiding clinical decision-making."

Retrospective data • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • ERBB3 • HER-2

Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing non- squamous EGFR wildtype advanced NSCLC: Updated analysis of the LUMINOSITY trial (JADPRO 2025) - "INTRODUCTIONTelisotuzumab vedotin (Teliso or TelisoV) is a B-class anti-c-Met antibody drug conjugate (ADC) that has demonstrated efficacy and a tolerable safety profile in preliminary studies.Preliminary data suggest a c-Met high protein expression status may enrich for response to TelisoV, though c-Met overexpression and c-Met activating mutations do not always overlap.The phase 2, multicenter, nonrandomized LUMINOSITY Trial (NCT03539944) evaluated TelisoV 5.6 mg/kg every 2 weeks (Q2W) in patients with previously treated, c-Met positive (IHC 2+ or 3+), non-squamous (NSQ) EGFR wildtype (WT) advanced NSCLC.LUMINOSITY Trial Cohort 4 (c-Met High) met the primary endpoint of objective response rate (ORR) in Stage 1.We present an updated safety and efficacy analysis of TelisoV 5.6 mg/kg Q2W in patients with c-Met protein overexpressing EGFR WT NSCLC (Cohort 4, c-Met High) from the LUMINOSITY Trial.METHODSEligible patients had histologically or cytologically confirmed stage..."

Clinical • Metastases • Monotherapy • Fatigue • Inflammation • Interstitial Lung Disease • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • EGFR • MET

Telisotuzumab vedotin endolysosomal trafficking is enhanced with osimertinib co-treatment in EGFRmut NSCLC (ESMO 2026) - No abstract available

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real World (RW) Uptake and Characteristics of Patients (Pts) Receiving Telisotuzumab Vedotin-tllv (Teliso-V) in Non-Small Cell Lung Cancer (NSCLC) From a US Claims Database (ESMO 2026) - No abstract available

Claims database • Clinical • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial. (PubMed, J Clin Oncol) - P2 | "Teliso-V was associated with durable responses in c-Met protein-overexpressing non-squamous EGFR-wildtype NSCLC, especially in those with high c-Met. AEs were generally manageable."

Journal • Metastases • Monotherapy • P2 data • Fatigue • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

Telisotuzumab vedotin monotherapy for previously untreated MET-amplified non-small cell lung cancer (JLCS 2023) - No abstract available

Monotherapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Telisotuzumab Vedotin (Teliso-V) Monotherapy in Patients (pts) with Previously Treated c-Met– Overexpressing (OE) Advanced Nonsmall Cell Lung Cancer (NSCLC) (AIOM 2023) - P2 | N=270 | LUMINOSITY (NCT03539536) | Sponsor: AbbVie | "Teliso-V demonstrated a promising ORR in pts with previously treated c-Met OE NSQ EGFR WT NSCLC; this cohort is currently expanding in Stage 2. ORR was modest in the cohorts of pts with c-Met OE NSQ EGFR mutant NSCLC and with c-Met OE SQ NSCLC; both cohorts have now met the protocol-specified stopping criteria and are no longer enrolling. The safety profile observed was consistent with IA3."

P2 data

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. (PubMed, JTO Clin Res Rep) - P2 | "Teliso-V monotherapy 1.9 mg/kg elicited durable responses, irrespective of the type of previous therapy received, and maintained a manageable safety profile in patients with c-Met protein overexpressing EGFR wild-type, nonsquamous NSCLC. NCT03539536."

IO biomarker • Journal • Monotherapy • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFRmutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study (AIOM 2023) - P1B | N=237 | (NCT02099058) | Sponsor: AbbVie | "T + O combination demonstrated tolerable safety and encouraging efficacy with an overall ORR of 50% and DCR of 75% in pts with EGFR-mut, c-Met OE NSCLC who progressed on prior O. This combination may be a potential 2L and 3L Tx option likely to benefit this specific population and deserves further clinical exploration."

P1 data

Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial (ESMO 2025) - P2 | "The most common TEAE leading to dose reduction or interruption was peripheral sensory neuropathy, a known cumulative toxicity associated with MMAE-based ADCs. These exploratory analyses suggest dose modifications due to TEAEs did not negatively impact efficacy."

Clinical • Metastases • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

LUMINOSITY, a phase 2 study of telisotuzumab vedotin in patients with c-Met protein–overexpressing non-squamous EGFR-wildtype advanced NSCLC: Efficacy outcomes by prior therapy. (ASCO 2025) - P2 | "This analysis demonstrated that Teliso-V elicited durable responses in pts with c-Met protein–OE NSQ EGFR-WT NSCLC regardless of whether they had received prior platinum or platinum + ICI therapies; the efficacy outcomes in these subgroups were consistent with those in the overall pt population. aPer independent central review. DOR, duration of response."

Clinical • IO biomarker • Metastases • P2 data • Fatigue • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor • EGFR • MET

FINAL PHASE 1b Study Results of Telisotuzumab Vedotin and OSIMERTINIB in ASIAN VS NON-ASIAN PATIENTS WITH ADVANCED NSCLC (JSMO 2024) - No abstract available

Clinical • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Peripheral Neuropathy and Efficacy of Telisotuzumab Vedotin in c-Met Protein-Overexpressing NSCLC: LUMINOSITY Study (IASLC-WCLC 2025) - P2 | "Patients with grade ≥3 PN (n=17) had a longer median duration of treatment and improved efficacy outcomes compared with those without grade ≥3 events (n=151). Although the number of patients with grade ≥3 PN was limited, these findings suggest that patients who develop these events are generally patients who remain on treatment for an extended time, indicating they are deriving benefit from Teliso-V."

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Pain • Solid Tumor • EGFR • MET

Telisotuzumabvedotin Demonstrates Potent Antitumor Efficacy in Preclinical Models of Diffuse Pleural Mesothelioma (IASLC-WCLC 2026) - "Conclusions : Teliso-V demonstrated robust and well-tolerated antitumor activity in multiple preclinical models of DPM through targeting MET overexpression. These findings support Teliso-V as a promising therapeutic candidate for MET-positive DPM and provide a compelling rationale for further clinical investigation."

IO biomarker • Preclinical • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pleural Mesothelioma • Solid Tumor • Thoracic Cancer • MET

Impact of genomic alterations measured in circulating tumor DNA (ctDNA) on clinical response to telisotuzumab vedotin treatment in patients with non-small cell lung cancer (NSCLC). (ASCO 2023) - P2 | "MET amp occurred more frequently in responders; however, Teliso-V activity was not restricted to these pts, as most responders were not MET amplified. Specific genomic alterations beyond MET may influence clinical response. The current analysis demonstrated numeric differences between pts with identified drivers who did or did not respond to Teliso-V."

Circulating tumor DNA • Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • KRAS • MET

Ocular surface disorders in patients with c-Met protein–overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study (ESMO 2025) - P2 | "Conclusions Ocular surface AEs seen in the LUMINOSITY study were low-grade (mostly grade ≤2) and manageable with protocol-recommended supportive care measures and/or dose modifications, and did not result in Teliso-V discontinuation. Proper pt education on the ocular effects of Teliso-V, along with timely identification and care, are important for effective management of these AEs."

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype (EGFRwt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE). (ASCO 2025) - P2 | "ctDNA is a promising biomarker in predicting Teliso-V activity. Confirmatory research is planned in larger pt cohorts and/or with tissue-based NGS analyses."

Circulating tumor DNA • Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • EGFR • FGFR3 • FGFR4 • HER-2 • KIF5B • KRAS • MET

Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), non-squamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY (AACR 2023) - P2 | "Teliso-V demonstrated a promising ORR in previously treated pts with MET Amp NSQ NSCLC with c-Met OE and improved PFS when compared to last prior systemic cancer therapy. These preliminary data support the ongoing Phase 2 trial of Teliso-V monotherapy in pts with previously untreated MET Amp NSCLC (TeliMET NSCLC-02; NCT05513703), which is currently enrolling."

Retrospective data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates (ESMO Asia 2023) - P1 | "Conclusions T + O showed tolerable safety and encouraging efficacy in pts with EGFR-mut, c-Met OE NSCLC with progression on O, regardless of MET amplification status or number of prior L, with an ORR of 53/50% and DCR of 71/76% as per investigators/ICR. T + O may be a potential option for these pts and warrants further clinical investigation."

Clinical • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Impact of MET amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ) EGFR wild-type (WT) NSCLC with c-Met protein overexpression (OE). (ASCO 2026) - P2, P3 | "MET amp is more common in pts with high c-Met OE in this retrospective subgroup analysis. Tumor activity with Teliso-V was observed regardless of MET amp status. The impact of MET amp in pts with c-Met OE will be further evaluated in ongoing Phase 3 study (NCT04928846)."

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Solid Tumor • CDK6 • EGFR • MET

Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY (IASLC-WCLC 2024) - P2 | "Compelling and durable responses were observed in patients of Asian race with c-Met protein-OE non-squamous EGFR WT NSCLC, especially in patients with c-Met high; these results are similar to the overall population. Teliso-V had an acceptable safety profile that was clinically manageable."

Clinical • IO biomarker • Infectious Disease • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Pneumonia • Respiratory Diseases • Solid Tumor • EGFR • MET

METRIX: International real-world (RW) study of c-Met protein overexpression (OE) in patients (pts) with locally advanced (LA)/metastatic NSCLC (ESMO 2025) - P2 | "Background In the LUMINOSITY study (NCT03539536), telisotuzumab vedotin, a c-Met (MET) protein-directed ADC, showed promising antitumor activity in pts with NSQ NSCLC with c-Met OE...Determining associations of c-Met OE with other biomarkers could aid therapy decisions. Table: 1923P Total Int c-Met OE High c-Met OE N=476 Y n=167 N n=309 Y n=106 N n=370 EGFR mutation, n/N (%) 118/430 (27) 46/153 (30) 72/277 (26) 30/98 (31) 88/332 (27) ALK1 translocation, n/N (%) 20/384 (5) 8/139 (6) 12/245 (5) 5/87 (6) 15/297 (5) ROS1 translocation, n/N (%) 9/367 (3) 5/132 (4) 4/235 (2) 4/84 (5) 5/283 (2) KRAS , n/N (%) 116/291 (40) 45/106 (43) 71/185 (38) 27/64 (42) 89/227 (39) BRAF, n/N (%) 13/310 (4) 4/111 (4) 9/199 (5) 3/75 (4) 10/235 (4) PD-L1, tumor proportion score ≥50%, n/N (%) 111/382 (29) 64/138 (46) 47/244 (19) 47/91 (52) 64/291 (22) MET amp, n/N (%) 10/117 (9) 7/48 (15) 3/69 (4) 5/34 (15) 5/83 (6) MET ex 14 skipping mutation, n/N (%) 4/213 (2) 4/80 (5) 0/133 (0) 3/54 (6)..."

Clinical • IO biomarker • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK1 • BRAF • EGFR • KRAS • MET • PD-L1 • ROS1